Axsome Therapeutics, Inc. (AXSM)
Data as of , from SEC Form 4 filings.
See up to 3 months of AXSM. The 7-day demo opens the 1M and 3M ranges and puts AXSM on your watchlist.
Start 7-day demoLatest AXSM insider trades
About Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. files with the SEC under CIK 0001579428 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
AXSM Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 3 | 59,664 | $12.62M |
| Option exercise | 6 | 119,328 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
AXSM insider transactions (Form 4)
6549 Form 4 filings on record, the earliest from Nov 20, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Option exercise | Common Stock | 10,000 | $12.95 | $130K | ||
| Open-market sale | Common Stock | 10,000 | $208.65 footnote F4 | $2.09M | ||
| Option exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 45,004 | $4.95 | $223K | ||
| Open-market sale | Common Stock | 45,004 | $212.01 footnote F4 | $9.54M | ||
| Option exercise | Common Stock | 4,660 | $4.95 | $23K | ||
| Open-market sale | Common Stock | 4,660 | $213.95 footnote F5 | $997K | ||
| Option exercise | Stock Option (Right to Buy) | 45,004 | $0.00 | - | ||
| Option exercise | Stock Option (Right to Buy) | 4,660 | $0.00 | - | ||
| ||||||
| Option exercise | Stock Option (Right to Buy) | 49,666 | $0.00 | - | ||
| Option exercise | Common Stock | 49,666 | $4.95 | $246K | ||
| Open-market sale | Common Stock | 49,666 | $240.25 footnote F4 | $11.93M | ||
| ||||||
| Open-market sale | Common Stock | 286 footnote F2 | $246.18 | $70K | ||
| Open-market sale | Common Stock | 286 footnote F2 | $249.12 | $71K | ||
| ||||||
| Option exercise | Restricted Stock Units | 1,429 | $0.00 | - | ||
| Option exercise | Common Stock | 1,429 footnote F1 | - footnote F2 | - | ||
| ||||||
| Mark E. Saad | Option exercise | Common Stock | 1,429 footnote F1 | - footnote F2 | - | |
| Mark E. Saad | Option exercise | Restricted Stock Units | 1,429 | $0.00 | - | |
| ||||||
| Susan Mahony | Option exercise | Restricted Stock Units | 1,429 | $0.00 | - | |
| Susan Mahony | Option exercise | Common Stock | 1,429 footnote F2 | - footnote F1 | - | |
| Susan Mahony | Open-market sale | Common Stock | 300 footnote F4 | $237.21 | $71K | |
| Susan Mahony | Open-market sale | Common Stock | 300 footnote F4 | $246.18 | $74K | |
| ||||||
| Mark Coleman | Open-market sale | Common Stock | 643 footnote F4 | $249.00 footnote F5 | $160K | |
| Mark Coleman | Option exercise | Restricted Stock Units | 1,429 | $0.00 | - | |
| Mark Coleman | Option exercise | Common Stock | 1,429 footnote F2 | - footnote F1 | - | |
| ||||||
| Mark Coleman | Grant or award | Restricted Stock Units | 1,721 | $0.00 | - | |
| Susan Mahony | Grant or award | Restricted Stock Units | 1,721 | $0.00 | - | |
| Option exercise | Common Stock | 49,670 | $4.95 | $246K | ||
| Open-market sale | Common Stock | 49,670 | $241.01 footnote F4 | $11.97M | ||
| Option exercise | Stock Option (Right to Buy) | 49,670 | $0.00 | - | ||
| ||||||
| Option exercise | Common Stock | 33,000 | $3.50 | $116K | ||
| Open-market sale | Common Stock | 33,000 | $240.09 footnote F4 | $7.92M | ||
| Option exercise | Stock Option (Right to Buy) | 33,000 | $0.00 | - | ||
| ||||||
| Mark E. Saad | Grant or award | Restricted Stock Units | 1,721 | $0.00 | - | |
| Grant or award | Restricted Stock Units | 1,721 | $0.00 | - | ||
| Mark Coleman | Open-market sale | Common Stock | 6,000 | $233.46 footnote F3 | $1.40M | |
| Mark Coleman | Open-market sale | Common Stock | 6,000 | $230.30 footnote F4 | $1.38M | |
| Mark Coleman | Open-market sale | Common Stock | 5,537 | $223.39 footnote F5 | $1.24M | |
| ||||||
| Option exercise | Common Stock | 4,517 | $12.95 | $58K | ||
| Open-market sale | Common Stock | 4,517 | $227.94 footnote F4 | $1.03M | ||
| Option exercise | Common Stock | 233 | $12.95 | $3K | ||
| Open-market sale | Common Stock | 233 | $228.18 footnote F5 | $53K | ||
| Option exercise | Stock Option (Right to Buy) | 4,517 | $0.00 | - | ||
| Option exercise | Stock Option (Right to Buy) | 233 | $0.00 | - | ||
| ||||||
| Grant or award | Performance Stock Units | 8,669 | $0.00 | - | ||
| Grant or award | Performance Stock Units | 24,081 | $0.00 | - | ||
| Ari Maizel - Officer | Option exercise | Common Stock | 7,500 | $70.73 | $530K | |
| Ari Maizel - Officer | Open-market sale | Common Stock | 7,500 | $182.42 footnote F3 | $1.37M | |
| Ari Maizel - Officer | Option exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | - | |
| ||||||
| Grant or award | Performance Stock Units | 8,188 | $0.00 | - | ||
| Hunter R. Murdock - Officer | Grant or award | Performance Stock Units | 7,224 | $0.00 | - | |
| Grant or award | Restricted Stock Units | 54,623 | $0.00 | - | ||
| Grant or award | Restricted Stock Units | 18,570 | $0.00 | - | ||
| Hunter R. Murdock - Officer | Grant or award | Restricted Stock Units | 16,385 | $0.00 | - | |
| Ari Maizel - Officer | Grant or award | Restricted Stock Units | 16,385 | $0.00 | - | |
| Mark Coleman | Open-market sale | Common Stock | 25,000 | $161.11 footnote F3 | $4.03M | |
| ||||||
| Option exercise | Common Stock | 35,378 | $2.85 | $101K | ||
| Open-market sale | Common Stock | 35,378 | $161.88 footnote F4 | $5.73M | ||
| Option exercise | Stock Option (Right to Buy) | 35,378 | $0.00 | - | ||
| ||||||
| Mark Coleman | Option exercise | Common Stock | 6,250 | $4.95 | $31K | |
| Mark Coleman | Option exercise | Stock Option (Right to Buy) | 6,250 | $0.00 | - | |
| Mark Coleman | Option exercise | Common Stock | 12,485 | $4.95 | $62K | |
| Mark Coleman | Option exercise | Stock Option (Right to Buy) | 12,485 | $0.00 | - | |
| Mark Coleman | Option exercise | Common Stock | 5,193 | $8.02 | $42K | |
| Mark Coleman | Option exercise | Stock Option (Right to Buy) | 5,193 | $0.00 | - | |
Recent AXSM Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Mark Jacobson | Officer | 10,000 | $2.08M | View on EDGAR | |
| Herriot Tabuteau | Officer | 4,660 | $979K |
AXSM insider trading FAQ
What is the latest insider trade for AXSM?
Axsome Therapeutics, Inc. (AXSM) had 2 insider filings in the last 90 days, with the most recent on 2026-09-03. The full record for AXSM runs to 49 Form 4 filings, the earliest from 2024-11-20. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying AXSM stock?
No insider purchases of AXSM were filed in the last 90 days. 3 purchases are on record for this company.
How many insiders are selling AXSM stock?
3 insider sales of AXSM were filed in the last 90 days, totaling $12.62M.
Where can I see AXSM SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects AXSM Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Mark L. Jacobson view on EDGAR
- - Herriot Tabuteau view on EDGAR
- - Herriot Tabuteau view on EDGAR
- - Roger Jeffs view on EDGAR
- - Roger Jeffs view on EDGAR
- - Mark E. Saad view on EDGAR
- - Susan Mahony view on EDGAR
- - Mark Coleman view on EDGAR
- - Mark Coleman view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where AXSM's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow AXSM with a 7-day demo
- AXSM on your watchlist
- Every AXSM Form 4 filing on record
- Up to 3 months of AXSM price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive